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Background: The role of endothelial progenitor cells (EPCs) in vascular repair is related to their recruitment at the
sites of injury and their interaction with different components of the circulatory system. We have previously shown
that EPCs bind and inhibit platelet function and impair thrombus formation via prostacyclin secretion, but the role
of EPC binding to platelet P-selectin in this process has not been fully characterized. In the present study, we assessed
the impact of EPCs on thrombus formation and we addressed the implication of P-selectin in this process.
Methods: EPCs were generated from human peripheral blood mononuclear cells cultured on fibronectin in conditioned
media. The impact of EPCs on platelet aggregation and thrombus formation was investigated in P-selectin
deficient (P-sel−/−) mice and their wild-type (WT) counterparts.
Results: EPCs significantly and dose-dependently impaired collagen-induced whole blood platelet aggregation
in WT mice, whereas no effects were observed in P-sel−/− mice. Moreover, in a ferric chloride-induced arterial
thrombosis model, infusion of EPCs significantly reduced thrombus formation in WT, but not in P-sel−/− mice.
Furthermore, the relative mass of thrombi generated in EPC-treated P-sel−/− mice were significantly larger than
those in EPC-treated WT mice, and the number of EPCs recruited within the thrombi and along the arterial wall
was reduced in P-sel−/− mice as compared to WT mice.
Conclusion: This study shows that EPCs impair platelet aggregation and reduce thrombus formation via a
cellular mechanism involving binding to platelet P-selectin. These findings add new insights into the role of
EPC-platelet interactions in the regulation of thrombotic events during vascular repair.
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Endothelial progenitor cells (EPCs) play a pivotal role in
vascular biology and homeostasis, as they enhance the
process of re-endothelialisation and neo-vascularization
of injured and ischemic tissues [1-5]. Interactions of
EPCs with vascular and blood cells can largely influ-
ence their biological activity and impact their recruit-
ment to target tissues. More specifically, interactions of
EPCs with circulating platelets enhance their functional
properties and provide the critical signal to ensure their
migration and homing at the sites of vascular injury,
thus facilitating their differentiation into endothelial
cells [6-12]. Indeed, platelets favor the adhesion of* Correspondence: yahye.merhi@icm-mhi.org
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unless otherwise stated.EPCs onto the sub-endothelial matrix, as they consti-
tute a bridging mechanism for the firm arrest of EPCs
on collagen surfaces under dynamic flow in vitro and
on the injured vessel wall in vivo [9,13]. This adhesive
interaction between EPCs and platelets may improve
EPC function and induce the secretion of various vaso-
active substances that can modulate the micro-
environment of the lesion, which in turn may enhance
vascular repair and accelerate the healing process.
Platelet aggregation represents the onset of thrombus
formation during endothelial disruption. At the sites of
vascular injury, platelets roll and interact with various
components of the sub-endothelial matrix via a num-
ber of adhesive receptors expressed on the platelet sur-
face [14]. This leads to the adhesion and activation of
platelets, which is accompanied by the translocation
and exposure of P-selectin (CD62P) on the membrane.ntral. This is an Open Access article distributed under the terms of the Creative
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molecules, is expressed primarily on activated platelets
[15] and promotes the interaction of platelets with
leucocytes [16]. In this regard, it has been shown that
P-selectin is also involved in the adhesive interaction
between platelets and EPCs, an interaction which re-
portedly dictates their functions during vascular repair
[6-9,13,17]. Indeed, previous studies have shown that
specific inhibition of P-selectin reduced the accumula-
tion of EPCs on the surface of collagen-adherent plate-
lets in parallel-plate flow chambers and at sites of
endothelial disruption [9,13].
The functional impact of EPC/platelet interactions was
indirectly explored in a number of studies showing that
EPCs participate in the prevention of hybrid graft
thrombosis and rejection and late stent thrombosis
[18-24]. Moreover, in a rat model of chronic thrombosis,
transplanted EPCs appear to alter the vein micro-
environment by up-regulating cytokines associated with
thrombi re-organization and recanalization [25]. Taken
together, this strongly suggests that EPCs may play a po-
tential role in the management of thrombotic reactions.
However, the direct effect of EPCs on the formation of
platelet aggregates, presumably a critical biological event
during the initial phase of thrombus formation, has not
been fully explored. Nevertheless, in our previous work,
we showed that human EPCs regulate platelet function,
via up-regulation of cyclooxygenase (COX)-2 and pros-
tacyclin (PGI2)-dependent inhibition of platelet activa-
tion, aggregation, adhesion, and thrombus formation
[26]. Given that platelet P-selectin is the major receptor
involved in the interaction of EPCs with platelets [6,8,9],
we accordingly speculated that the impact of EPCs on
platelet function occurs through a mechanism that in-
volves platelet P-selectin. We, therefore, designed this
study to depict the role of P-selectin in this process by
assessing platelet aggregation and thrombus formation
in wild type (WT) and P-selectin deficient (P-sel−/−)
mice. We demonstrate that P-selectin is a determinant
adhesive receptor involved in the recruitment of EPCs
into the platelet thrombi and along the injured vessel
wall. Moreover, we found that P-selectin plays a key role
in mediating the inhibitory effect of EPCs on platelet ag-
gregation in vitro and thrombus formation in vivo. This
study adds new insight into the interplay between EPCs
and platelets in the maintenance of vascular hemostasis
and the management of thrombotic reactions.
Methods
Mice
Female 12 to 14 week-old C57BL/6 P-sel−/− and their
counterparts C57BL/6 WT mice were purchased from
Jackson Laboratory (Bar Harbor, ME). This study was
carried out in strict accordance with the recommendationsin the guide for the care and use of laboratory animals
of the Canadian council for animal care. The protocol
was approved by the committee on the ethics of animal
experiments of the Montreal heart institute. All surgery
was performed under a mixture of ketamine (Vetalar:
1.5 mg/kg I.P., Bioniche, Belleville, ON) and medetomi-
dine (Domitor: 1 mg/kg I.P., Pfizer, Kirkland, QC).
Culture and characterization of human EPCs
Human EPCs were generated from peripheral blood
mononuclear cells (PBMCs) collected from the anticu-
betal vein and cultured for 10 days on fibronectin in
the presence of EndoCultTM medium, as previously
described [26]. Changes in cell morphology during the
differentiation process were assessed by optical micros-
copy, whereas changes in the expression of cell surface
markers were assessed by flow cytometry, as previously
described [26]. This study was approved by the ethical
committee of the Montreal heart institute. All human
subjects were healthy volunteers of either sex, aged
between 20 and 55 years old. They gave written in-
formed consent prior to participating in the study and
were free from any drugs that interfere with platelet
function.
Platelet aggregation
Blood was drawn by cardiac puncture, from anesthe-
tized mice with a mixture of 75 mg/kg of Ketamine
(Vetalar, Belleville, QC) and 0.5 mg/kg of medetomi-
dine (Domitor, Pfizer , Kirkland, QC), in 1-cc syringes
containing 50 μL of heparin (100 IU/mL) [27,28]. Blood
was then subjected to the aggregation process in a 4
channel whole blood platelet aggregometer (Chrono-log
corp., Havertown, PA), as previously described [28-31].
Briefly, blood was diluted 1:1 with 0.4 mL of saline
solution. Fresh culture media (200 μL) or EPCs (125 × 103
to 500 × 103 cells/200 μL) were added to the sample of
diluted blood, and allowed to warm to 37°C for 5 minutes.
Platelet aggregation was induced by collagen (3 μg/mL,
Chrono-log corp.) at 37°C with a stirring speed of
1000 rpm, and was expressed as the change in electrical
impedance (ohms) after 5 minutes of aggregation time.
Mouse carotid thrombosis
The effects of EPCs (125 × 103 to 500 × 103 cells) on
thrombus formation were determined in a ferrous
chloride (FeCl3)-mouse carotid injury model, according
to a standardized protocol [26,32], and as described in
our previous work [26]. Control experiments were done
with fresh culture media alone. Briefly, P-sel−/− and
WT mice were anesthetized and the right carotid artery
was carefully exposed. A miniature ultrasound flow
probe (0.5 VB 552; Transonic Systems, Ithaca, NY),
interfaced with a flow meter (T206; Transonic Systems)
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analyzed through a computer-based data acquisition
program (Iox 2.2.17.19, Emka, Falls Church, VA). After
measuring baseline blood flow, a 0.5 × 1.0-mm strip of
filter paper (Whatman no. 1) soaked in 6.5% FeCl3 was
applied on the adventitial surface proximal to the flow
probe for 3 min, after which blood flow and time to
thrombotic occlusion (blood flow of 0 mL/min) were
monitored.Histology, immune-staining and confocal fluorescence
After completion of in vivo blood flow measurements in
thrombosis mice model, the injured and contralateral non-
injured carotids were excised and fixed in 10% buffered
Formalin (Starplex Scientific Inc., Etobicoke, ON). These
arterial segments were then embedded in paraffin, sec-
tioned at 6 microns, and stained with hematoxylin and
eosin, or an anti-CD34 antibody (Santa Cruz). Sections
were visualized using an Olympus BX60 microscope
(Olympus imaging America Inc., Center Valley, PA) and
the computerized morphometric analyses were performed
using a Retiga 2000R camera (QImaging Corporation,
Surrey, BC), and Image Pro Plus 6.2 software (Media
Cybernetics, Bethesda, MD).Figure 1 Morphological change of PBMCs-derived EPCs in vitro. Adherence, se
inverted optical microscopy. A) At day 0, freshly isolated PBMCs were plated on
morphology. B) At day 3, the adherent cells appear either as single cells or as i
form a central cluster of round cells with elongated spindle-like cells at the perFor confocal fluorescence, 500 × 103 EPCs were labeled
with an intracellular fluorescent marker (CellTrackerTM
CM-DiI, Molecular Probes) according to the manufac-
turer’s instructions. Non-labeled PBMCs were used as
negative control. Cells were then washed with PBS, resus-
pended in fresh media, injected intravenously, and allowed
to circulate for 15 minutes before mouse carotid injury in-
duction. The injured as well as the contralateral non-
injured carotids were excised immediately after completion
of blood flow measurements and immersed in liquid nitro-
gen. Labeled EPCs incorporated into the luminal aspect of
arterial thrombi were observed on cryostat sections of 14-
μm thickness using confocal microscopy [26].
Statistical analysis
All data are presented as mean ± SEM of at least 4 inde-
pendent experiments. Statistical comparisons were done
using a one-way ANOVA, followed by Benferroni multiple
comparisons test. Data with P <0.05 were considered sta-
tistically significant.
Results
Phenotypic characterization of EPCs
We followed the differentiation of PBMCs into EPCs
in vitro using optical microscopy. As shown in Figure 1,quential changes and differentiation of PBMCs are observed under
fibronectin and the majority of cells are non-adherent with a rounded
rregular colony-like structures. C) At day 5, colonies are better defined and
iphery. D) At day 10, cells show a flat monolayer of spindle-shaped cells.
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with rounded morphology. Cultured in conditioned
media, PBMCs started to assemble into colony-like
structures with irregular size after 3 days of culture. At
day 5, the colonies became more organized and con-
sisted of a central cluster of round cells and sprouts of
elongated cells at the periphery, a characteristic of the
colony forming units-endothelial cells. After 10 days, the
cells formed a monolayer of spindle-shaped flat cells
characteristic of EPCs.
To further characterize the differentiation of PBMCs
into EPCs, we employed flow cytometry to quantify the
expression of typical markers on the surface of the cells
during their differentiation (Figure 2). Cells were gated
with respect to CD14/CD34 expression. We observed that
freshly isolated PBMCs highly expressed the pan-leukocyte
markers CD14 (86% ± 2%), whereas the progenitor/endo-
thelial markers CD34 and vascular endothelial growth
factor receptor 2 (VEGFR2) were missing (Figure 2). After
10 days of culture, progenitor/endothelial markers were
expressed (56% ± 2% CD34 and 30%± 5% VEGFR2),
whereas the leukocyte marker CD14 was absent (Figure 2).Figure 2 Expression of cell surface markers. A) Representative overlay plot
flow cytometry. Single color immunostaining of freshly isolated PBMCs at d
performed with saturating concentrations of mouse anti-human PE-conjug
Overlay plots are presented as the number of events over the log of assoc
least 4 independent experiments.Based on these characteristics, we used EPCs after 10 days
of culture in the following experiments.
EPCs inhibited platelet aggregation and thrombus
formation in a P-selectin-dependent manner
The effect of EPCs on platelet function was first assessed
in vitro by aggregation assays. Addition of EPCs to whole
blood from WT mice inhibited collagen-induced platelet
aggregation in a concentration-dependent manner, ranging
from 22% inhibition with 125 x 103 EPCs to 75% inhibition
with 500 x 103 EPCs (Figure 3A and B). In contrast, EPCs
were unable to significantly affect aggregation of platelets
from P-sel−/− mice (Figure 3C and D).
Having shown the importance of platelet P-selectin in
this process, we sought to determine its role in in vivo
thrombus formation using a murine model of carotid
thrombosis. Intravenous injection of increasing concen-
trations of EPCs in WT mice resulted in an increment
of arterial blood flow and prolongation of time to occlu-
sion in a concentration-dependent manner (Figure 4).
Similarly to platelet aggregation, the highest rates of blood
flow were reached with a concentration of 500 × 103s showing the expression of cell surface markers, as determined by
ay 0 (black plots) and culture-derived EPCs at day 10 (gray plots) was
ated monoclonal antibodies directed against CD14, CD34 and VEGFR2.
iated fluorescence. B) Histogram represents the mean data ± SEM of at
Figure 3 Effect of EPCs on collagen-induced platelet aggregation. Whole blood was pre-incubated with different concentrations of EPCs in
a 4-channel lumi-aggregometer under shear (1,000 rpm) at 37°C. Platelet aggregation was initiated by adding collagen (3 μg/mL) and then
monitored for 5 minutes. Representative traces of whole blood platelet aggregation from A) WT and B) P-sel−/− mice. The mean data ±
SEM of 5 independent experiments, summarizing the effects of different EPC concentrations on collagen-induced platelet aggregation in
WT and P-sel−/− mice are presented in C and D, respectively.
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observable in P-sel−/− mice, in which injection of 500 ×
103 EPCs induced similar blood flow measurements to
control treated mice that received fresh culture media
(Figure 4).
To further analyze the characteristics of the formed
thrombus, injured carotid arteries from WT and P-sel−/−
mice were fixed and subjected to histological and
morphometrical analysis. Carotids from culture media-
treated mice were used as negative control. The circum-
ferences of the arteries and thrombi were measured by
computer-assisted planimetry, and the thrombus size
was reported as percentage of total lumen area. In com-
parison to control- and PBMC-treated mice, in which
the thrombus was completely occlusive (Figure 5A,
panels A and B), the thrombus size in EPC-treated mice
was visually decreased (Figure 5A, panel C). Indeed, in-
jection of 500 × 103 EPCs into WT mice lead to a 47%
reduction in thrombus mass (Figure 5A panel C and
Figure 5B). In contrast, P-sel−/− mice were unresponsive
to this treatment, as EPCs failed to induce significant
effects and the thrombus formed was almost occlusive
(Figure 5A, panel D and Figure 5B).
Hence, these results indicate that the presence of P-
selectin is of utmost importance, first to promote theinteraction between EPCs and platelets, and second to
sustain their mechanism of action on platelet aggrega-
tion and thrombus formation.
EPCs are recruited to the sites of injury through P-selectin
The role of P-selectin on EPCs’ impairment of thrombus
formation was further depicted by assessing their re-
cruitment into the sites of injury. FeCl3-injured carotid
arteries from EPC- and PBMC-treated mice (WT and
P-sel−/−) were immediately fixed following blood flow
measurements and subjected to fluorescence confocal
and immunohistochemical analysis. EPCs were labeled
with a photostable fluorescent cell tracker prior to intra-
venous injection. Labeled EPCs were identified in the
luminal aspect of the thrombi and appeared as a cluster
of red fluorescent clumps in the carotids of WT mice
(Figure 6D), and to a lesser extent in those of P-sel−/−
mice (Figure 6G). Injured arteries from unlabelled
PBMC-treated mice, used as negative control, were void
from any staining (Figure 6A). In accordance with morpho-
metrical analysis, the mass of thrombi generated in PBMC-
treated mice showed a complete occlusion (Figure 6B),
whereas thrombi mass was partially occlusive in WT mice
treated with 500 × 103 EPCs (Figure 6E). As expected,
thrombi mass was majorly occlusive in P-sel−/− mice
Figure 4 Effect of EPCs on thrombus formation. Fresh culture media or EPCs were infused and allowed to circulate for 5 minutes, followed by
application of FeCl3 for 3 minutes and continuously monitoring of carotid blood flow for 20 minutes post-FeCl3 injury. Thrombus formation in WT
and P-sel−/− mice infused with fresh culture media (Black line, n = 7) or with 500 x 103 cells/mouse (Green line, n = 7). Insert: Effects of increasing
concentrations of EPCs ranging from 125 x 103 cells/mouse (red line, n = 7), 250 x 103 cells/mouse (blue line, n = 7), or 500 x 103 cells/mouse
(green line, n = 7) in WT mice.
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of experiments, cross-histological sections of injured ar-
teries from PBMC- and EPC-treated mice were immu-
nostained with an anti-CD34 antibody. CD34 positive
cells were uniformly distributed within the thrombus
and along the vascular wall of EPC-injected WT mice
(Figure 6F), but poorly distributed in mice from the P-
sel−/− group (Figure 6I). The carotids of PBMC-treated
mice (negative control) showed no staining (Figure 6C).
All together, these data confirm that, in addition to its
role in mediating EPC/platelet interactions, P-selectin
promotes and sustains the anti-thrombotic effects of
EPCs.
Discussion
The present study provides novel insights into the
biology of EPCs and their interaction with activated
platelets. Specifically, we assessed the impact of EPCs
on platelet aggregation and thrombus formation and
we highlighted the role of platelet P-selectin in this
process. We found that EPCs inhibit platelet aggrega-
tion in vitro, incorporate into the formed thrombi and
along the vessel walls, and reduce thrombus extent
in vivo. Moreover, we provide evidences that theinhibitory action of EPCs on platelet aggregation and
thrombus formation is largely P-selectin dependent.
Arterial thrombosis with its clinical cardiovascular
complications is a multi-step process that is initiated by
the formation of a platelet aggregate at sites of vessel in-
jury. Depending on the mass of the generated thrombus,
partial or complete obstruction of blood flow may occur
within the injured artery, which can lead to acute coron-
ary syndromes and myocardial infarction. This process is
governed by specific cell adhesion molecules which
induce homotypic and heterotypic binding between
platelets and other blood cells [33,34]. Among these, P-
selectin has emerged as an important cell-cell inter-
action mediator which contributes, among others, to the
recruitment of blood leukocytes [16] and circulating
EPCs [6-9,13,17]. In addition to its role in thrombosis
and inflammation, P-selectin has been shown to induce
migration, homing and differentiation of EPCs at the
sites of vascular lesion [6-10].
The role of EPCs in the maintenance of vascular integ-
rity and as "repair" cells in response to endothelial injury
is well recognized. Indeed, EPCs circulate within the
blood as "surveillance" cells encountering only transitory
contacts with the intact vascular endothelium. When
Figure 5 Histological cross-sections of FeCl3-injured mouse carotid arteries. A) Representative histological transverse sections of FeCl3-injured
mouse carotid arteries treated with EPCs, PBMCs, or fresh culture media (control) and stained with hematoxylin and eosin. (Magnifications 20X).
Arterial thrombus mass was completely occlusive in control-and PBMC-treated mice (panels A & B, n = 4) and partially occlusive in arteries from
EPC-treated mice (panel C, n = 4). Panel D represent the injured artery from P-sel−/− mice treated with 500 x 103 EPCs (n = 4). B) Histogram
represents the mean data ± SEM of cross-sectional area of arterial thrombi expressed as percentage of lumen area.
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autocrine and paracrine mechanisms, in the normal
response to injury. Requirement of vascular repair is
communicated to circulating EPCs by adherent/aggre-
gated platelets at sites of vessel damage.
The use of ex vivo-expanded EPCs has been shown to
improve re-endothelialisation and neovascularization of
ischemic hind limbs and ischemic hearts in animal
models, as well as in the prevention of hybrid graft
thrombosis, restenosis and rejection [18-24,35,36]. In
particular, in a rat model of chronic thrombosis,
transplanted EPCs appear to alter the vein micro-
environment by up-regulating cytokines associated
with thrombus re-organization and recanalization [25].
Moreover, recent clinical studies have provided ample
evidence that the use of EPC-capture stents conceiv-
ably limits the cascade of events leading to acute or
sub-acute stent- and late-stent thrombosis [22,23].
Taken together, these results highlight the potential
role that EPCs may play in the management ofthrombotic reactions. However, the direct effect of
EPCs on platelet aggregation, a critical biological event
during the initial phase of thrombus formation, has not
been extensively studied. Nevertheless, we have previ-
ously demonstrated that EPCs bind and inhibit platelet
aggregation in vitro and reduce thrombus formation
in vivo [26]. However, the therapeutic effects of EPCs
in cell therapy may stem from factors other than the
cells themselves, as very low numbers are incorporated
into capillaries post ischemia [37-39]. Instead, this im-
portant phenomenon may rather be related to their
ability to release pro-angiogenic factors. In accordance
with this hypothesis, we and others have previously
shown that EPCs release various vasoactive substances
in the micro-environment of the injury including an-
giogenic and growth factors, vascular endothelial
growth factor, hepatocyte growth factor, stromal-
derived factor, granulocyte colony-stimulating factor,
insulin-like growth factor as well as PGI2 and nitric
oxide (NO) [9,10,21,25,26,40-43]. In fact, PGI2 and NO
Figure 6 Fluorescent confocal imaging and immunostaining of FeCl3-injured mouse carotid arteries. Photomicrographs show fluorescent
confocal imaging and immunostaining of mouse carotid arteries after vascular injury. EPCs were labeled with an intracellular fluorescence marker
(DiL) 1 hour prior to injection in WT (Panel D) and P-sel−/− (Panel G) mice and assessed by confocal fluorescence on cryostat cross-sections. Panel
A represent the injured arteries from non-labeled PBMC-treated mice used as negative control. The corresponding Differential Interference
Contrast (D.I.C) of the identical sections of each carotid is shown on the right (panels B, E & H). (Scale bar = 50 μm). Anti-CD34 immunostaining of
the injured arteries in EPC-treated mice show that CD34 positive cells were uniformly distributed within the thrombus and along the vessel wall
in WT - but poorly distributed in P-sel−/− mice confirming the recruitment of EPCs to the luminal aspect of arterial thrombi in vivo (arrows in F
and I). The cells in C are CD34 negative. The images are representative of at least 4 independent experiments.
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leased from EPCs in large quantities in response to
various stimuli [21]. However, the release of anti-
platelet mediators near the damaged endothelium can
enhance angiogenesis, inhibit platelet aggregation and
limit thrombogenesis [26,44,45]. In our pervious study,
we have shown that both EPCs and their supernatants
were able to inhibit platelet aggregation and thrombus
formation. Analysis of EPC supernatants revealed the
presence of anti-thrombotic substances released by
EPCs in culture such as PGI2 and NO. Moreover, the
incubation of cultured EPCs with different PGI2 andNO inhibitors revealed that the inhibition of platelet
function is predominantly PGI2-dependent. In tissues,
PGI2 acts in paracrine manner, has a very short half-
life and is rapidly metabolized into 6-keto-PGF1α,
which is a weaker platelet inhibitor. In the present
study, we speculate that the adhesive interaction
between EPCs and platelets, via P-selectin, may create
a biochemical microenvironment that favors the secre-
tion of PGI2 by EPCs and optimize its biological
activity on bound platelets at the site of vascular injury
and thrombus formation. This may explain in part our
observation that a physical link between EPCs and
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on thrombosis.
In this regard, it has been shown that P-selectin can
mediate the rolling of platelets on activated endothelium
and various cell types including EPCs. These adhesive
interactions may enhance EPC activity and induce the
generation of intracellular signals leading to the secre-
tion of various vasoactive and anti-thrombotic sub-
stances that can modulate the micro-environment of the
lesion and alter thrombus formation. However, this issue
needs to be further addressed in detail to fully validate
this intriguing possibility.
In the present study, we have shown that EPCs impair
platelet aggregation and thrombus formation through P-
selectin-dependent EPC/platelet interactions. Our find-
ings are in accordance with studies from other groups
showing that blockade or lack of P-selectin drastically
reduces the accumulation of EPCs on the surface of ad-
herent platelets and at the sites of endothelial denuda-
tion [9,13]. Accordingly, we have adequately succeeded
to demonstrate that in deficient mice, the lack of P-
selectin has substantially compromised the adhesive
interaction between EPCs and platelets and conse-
quently reversed the inhibitory effect of EPCs on platelet
aggregation in vitro and thrombus formation in vivo.
The importance of EPC/platelet interactions in vascular
biology was further validated by our cell recruitment
data, which show that EPCs are recruited to the
thrombus mass in a process that depends upon P-
selectin. These findings may be of important physio-
logical relevance in vascular homeostasis since EPCs
must integrate into blood vessels and platelet thrombi
to improve neovascularization and limit thrombogen-
esis. However, our data leaves open which ligand on
EPCs is necessary for platelet P-selectin mediated inter-
action. This is due to the heterogeneity of EPC popula-
tions found in the circulation or differentiated in
culture and to the diversity of cell adhesion molecules
expressed on their surfaces. Nevertheless, we showed
that PBMC-derived EPCs bind activated platelets in a P-
selectin-dependent manner, thus confirming previous
findings demonstrating that the interaction between
platelets and EPCs occurs, in part, via P-selectin and
its high affinity receptor PSGL-1. However, this does
not rule out the involvement of other mediators such
as SDF-1α, CXC chemokine receptor-2 and −4, and β1-
and β2-integrins, which may also participate in EPC
binding to platelets and homing at the sites of vascular
injury [6-10,13,17,46,47].
Conclusions
Endothelial progenitor cells represent a promising thera-
peutic approach for the treatment of cardiovascular
diseases. Interaction of EPCs with platelets is critical fortheir recruitment and the fulfillment of their potential
therapeutic properties during vascular repair. In this
study, we provided novel insights into the central role
of P-selectin in the recruitment and interaction of
EPCs with platelets at the sites of vascular injury
mainly within the thrombi and along the vessel wall.
In addition, we demonstrated that EPCs inhibit plate-
let aggregation and thrombus formation through a
mechanism that involves the engagement of P-
selectin; thus highlighting the therapeutic potential of
EPCs, which may be relevant to the management of
atherothrombosis during acute coronary syndromes
and following percutaneous coronary interventions. In
addition to the well-documented roles of EPCs in
angiogenesis and vascular repair, our findings high-
light a new biological role for EPCs in regulating
platelet function via P-selectin. Ultimately, this may
lead to the development of novel EPC-derived anti-
thrombotic therapies in patients with cardiovascular
diseases.
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